0000950170-24-007559.txt : 20240125
0000950170-24-007559.hdr.sgml : 20240125
20240125175059
ACCESSION NUMBER: 0000950170-24-007559
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240123
FILED AS OF DATE: 20240125
DATE AS OF CHANGE: 20240125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Waltermire Robert E.
CENTRAL INDEX KEY: 0001876996
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33277
FILM NUMBER: 24563442
MAIL ADDRESS:
STREET 1: FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE
STREET 2: SUITE 200
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001157601
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
BUSINESS PHONE: 404-380-9263
MAIL ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20010815
4
1
ownership.xml
4
X0508
4
2024-01-23
0001157601
MADRIGAL PHARMACEUTICALS, INC.
MDGL
0001876996
Waltermire Robert E.
C/O MADRIGAL PHARMACEUTICALS, INC.
200 BARR HARBOR DRIVE, SUITE 200
WEST CONSHOHOCKEN
PA
19428
false
true
false
false
Senior VP, Chief Pharma Dev.
false
Common Stock
2024-01-23
4
A
false
1419
0
A
6536
D
Stock Option (Right to Buy)
229.00
2024-01-23
4
A
false
2138
0
A
2031-01-23
Common Stock
2138
2138
D
Market Stock Unit
2024-01-23
4
A
false
1419
0
A
Common Stock
1419
1419
D
Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.
**As attorney-in-fact for Reporting Person
/s/ Brian J. Lynch**
2024-01-25